中国药物相关死亡分析:自发报告系统研究
本研究基于中国多省药物警戒数据库,分析1,731例死亡个体病例安全报告(ICSR)的特征。结果显示死亡ICSR占所有严重病例的0.95%、所有报告的0.05%,0-4岁和>64岁患者报告率较高,20-34岁女性报告率超过男性。头孢曲松钠、地塞米松和清开灵注射液(中药注射剂)位列涉及药物前五位。
要点
- 幼儿和老年患者药物相关死亡风险高于5-64岁人群。
- 20-34岁育龄女性药物相关死亡风险高于同龄男性。
- 头孢曲松钠、地塞米松和清开灵注射液是涉及死亡报告较多的药物。
核心结论
- 幼儿和老年患者药物相关死亡风险高于5-64岁患者,20-34岁女性风险高于男性。
- 需加强幼儿、老年及育龄女性用药安全研究,药物警戒数据库是重要资源。
研究设计与样本
- 基于中国多省药物警戒数据库的死亡ICSR描述性统计分析。
- 共纳入1,731例死亡ICSR,涉及3,861种药物。
主要发现
- 死亡ICSR占所有严重病例的0.95%,占所有报告ICSR的0.05%。
- 78.57%的死亡ICSR由医疗机构报告,仅16.00%由生产商或经销商报告。
- 0-4岁年龄组死亡ICSR报告率显著高于5-64岁患者,>64岁患者报告率最高。
- 男性死亡ICSR报告率总体高于女性,但20-34岁年龄组女性报告率超过男性。
- 涉及药物中,头孢曲松钠146条(3.78%)居首,地塞米松131条(3.39%)第二,清开灵注射液75条(1.94%)第五。
临床怎么用
- 对幼儿、老年及20-34岁女性患者用药时需特别关注安全性。
- 中药注射剂如清开灵注射液的使用应加强监测与风险防范。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Adverse drug reactions with an outcome of death represent the most serious consequences and are inherently important for pharmacovigilance. The nature and characteristics of drug-related deaths are to a large extent unknown in the Chinese population. This study aims to characterize drug-related deaths by analysis of individual case safety reports (ICSRs) with an outcome of death in China. Methods: The characteristics of death ICSRs were analyzed by descriptive statistics of a large multi-provincial pharmacovigilance database in China. Results: There were 1,731 ICSRs with an outcome of death, representing 0.95% of all serious cases and 0.05% of all reported ICSRs. Most death ICSRs (78.57%) were reported by medical institutions. Only 16.00% of death ICSRs were reported by manufacturers or distributors. The reporting rate of death ICSRs in the age group of 0-4 years was significantly higher than patients aged 5-64 years. Patients aged over 64 years had the highest reporting rate of death ICSRs. Male patients generally had a higher reporting rate of death ICSRs than female patients. However, the reporting rate of female patients exceeded that of male patients in the age group of 20-34 years. Among 3,861 drugs implicated, ceftriaxone sodium with 146 (3.78%) records of death ranked first. Dexamethasone with 131 (3.39%) records of death ranked second. Qingkailing, an injectable traditional Chinese medicine with 75 (1.94%) records of death, ranked the fifth most frequently implicated medicine. Conclusion: Young children and elderly patients have a higher risk of drug-related deaths than patients aged 5-64 years. Female patients generally have a lower risk of drug-related deaths than male patients. However, female patients of reproductive age (aged 20-34 years) have a higher risk of drug-related deaths than male patients, hinting that physiological changes and drug uses for child bearing, giving birth, or birth control may significantly increase the risk of death for female patients aged 20-34 years. This paper suggests more research on the safe use of drugs for young children, elderly patients, and female patients of reproductive ages. Pharmacovigilance databases can be valuable resources for comprehensive understanding of drug-related problems.
引用
- Li H, Deng J, Yu P, et al. Drug-Related Deaths in China: An Analysis of a Spontaneous Reporting System. Front Pharmacol. 2022. PMID: 35281929. doi:10.3389/fphar.2022.771953
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。